Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1557746 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $5.12Day −3.94%Mkt cap $715M1Y +230.3%Off 52W high −12.9%Vol (1Y) 96.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,715 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.6% of sh out |
| Days to cover6.9d |
| 13F net flow (QoQ)−2.26% |
| Top-10 13F concentration60.6% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$8.4M |
| Earnings (TTM)-$69.7M |
| ROE−50.2% |
| Net margin−829.6% |
| Sales growth 3Y−35.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+70.1% |
| 1Y+230.3% |
| 3Y−48.1% |
| 5Y−66.8% |
| 10Y−74.0% |
| Since incept. (ann.)−6.9% |
Total return through 2026-07-29 · series begins 2015-10-07. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)96.8% |
| Ann. volatility (3Y)104.9% |
| Sharpe (1Y)1.57 |
| Sharpe (3Y)0.51 |
| Max drawdown (1Y)−36.6% |
| Max drawdown (3Y)−93.5% |
| Beta (3Y vs SPY)0.92 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BML Capital Management, LLC | 14.3M | $53M | 10.20% | +0.0% |
| Deep Track Capital, LP | 9.3M | $35M | 6.69% | new |
| BlackRock, Inc. | 7.4M | $28M | 5.30% | +8.8% |
| RA CAPITAL MANAGEMENT, L.P. | 6.8M | $26M | 4.87% | new |
| Vivo Capital, LLC | 6.7M | $25M | 4.77% | −25.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2M | $19M | 3.70% | new |
| Frazier Life Sciences Management, L.P. | 4.9M | $18M | 3.53% | new |
| Rock Springs Capital Management LP | 4.5M | $17M | 3.20% | +0.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.15 | — | $2.0M | +37.2% |
| 2025-12-31 | 2026-02-26 | — | — | $1.3M | −85.9% |
| 2025-09-30 | 2025-11-06 | −$0.12 | — | $3.3M | −24.1% |
| 2025-06-30 | 2025-08-07 | −$0.13 | — | $1.8M | −35.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
